Ads
related to: cholesteryl ester vs cetp 50 count- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Co-Pay Program
Resources
to Support Your Patients
- Trial Results
See Clinical Data
and Trial
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Dosing & Administration
consumereview.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
1071 n/a Ensembl ENSG00000087237 n/a UniProt P11597 n/a RefSeq (mRNA) NM_000078 NM_001286085 n/a RefSeq (protein) NP_000069 NP_001273014 n/a Location (UCSC) Chr 16: 56.96 – 56.98 Mb n/a PubMed search n/a Wikidata View/Edit Human Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein, is a plasma protein that facilitates the transport of cholesteryl esters and ...
Cholesteryl ester is transported from high-density lipoproteins (HDLs) to low-density lipoproteins (LDLs) and very low-density lipoproteins (VLDLs) with cholesteryl ester transfer protein (CETP). [5] The decrease in cholesteryl ester can lower HDL and increase LDL, which may be an indicator of cardiovascular problems, as indicated by ...
A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein (CETP). [1] [2] ...
The cholesterol is converted to cholesteryl esters by the enzyme LCAT (lecithin-cholesterol acyltransferase) for sstorage. The cholesteryl esters can be transferred, with the help of CETP (cholesterylester transfer protein) in exchange for triglycerides, to other lipoproteins (such as LDL, VLDL, IDL). These other lipoproteins can be eventually ...
CETP inhibitors (cholesteryl ester transfer protein), 1 candidate is in trials. (Anacetrapib) It is expected that these drugs will mainly increase HDL while lowering LDL; Squalene synthase inhibitor; ApoA-1 Milano; Succinobucol (AGI-1067), a novel antioxidant, failed a phase-III trial.
Dalcetrapib [4] (INN, codenamed JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. [5] [6] DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights into the development ...